PHATHOM PHARMACEUTICALS INC

Phathom insider sale shows shifting confidence: Robert Charles sells 1,555 shares at $11.04 amid a 10% weekly drop, hinting at cautious outlook on GI drug pipeline.

Phathom insiders’ buy‑sell pattern signals confidence in its GI drug pipeline and a potential upside, offering investors a “buy‑the‑dip” chance amid negative P/E.

Insider buying at Phathom Pharmaceuticals signals confidence: Parikh Asit adds 24,122 shares, sparking a 377 % social‑media buzz and a potential buying window before upcoming clinical milestones.

Phathom Pharmaceuticals sees insider confidence surge as Heidi Fields buys 24,122 RSUs—boosting investor optimism amid GI‑therapy pipeline milestones.

Phathom Pharmaceuticals insider Parikh Asit sells 40,000 shares and moves them to a spouse‑benefit trust, signaling a strategic wealth‑management move rather than a cash exit.

Insider buying by Phathom’s chief accountant shows cautious optimism: Breedlove’s recent RSU and PSU purchases hint at confidence amid volatile stock and a negative P/E.

Insider buy by Phathom owner Parikh Asit at $10.30 shows confidence that the drug‑maker is undervalued, but the trade is small and lacks market buzz, so investors should watch for new clinical or partnership data before betting on a rebound.